Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Nicotine Intake and Smoking Lapse
NCT05530577Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in Tobacco Use Disorder (TUD), nicotine dependence (ND), sponsored by University of North Carolina at Chapel Hill. Started Oct 2022; status: completed.
02
Drugs
03
Conditions
Tobacco Use Disorder (TUD)nicotine dependence (ND)
Beyond the preview
Go deeper on NCT05530577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05530577.